Investigations into the mechanism of action of rapamycin, a macrolide inhibitor of mTOR generated by bacteria with a wide range of clinical applications such as an antifungal, immunosuppressant, and anti-cancer medication, have yielded several insights into mTOR signaling (Sehgal, 2003). The gene discussed is MTOR; the disease is cancer.